M2Gen, the Oncology Research Information Exchange Network (ORIEN), and pharma companies are teaming up on a new way to bring clinical trials to advanced-stage cancer patients. This partnership, the ORIEN Avatar Research Program, will generate information on cancer patients, including the molecular characteristics of their cancers. Why is this important? Multiple reasons. Patients win by receiving increased access to new trials and new treatments. Pharma wins by creating a large database of patient information to analyze in the pursuit of personalized cancer treatments and having the ability to match patients to trials, cutting patient recruitment timelines and costs.